G1 THERAPEUTICS INC. - COMMON STOCK

G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05 Mar 2021 16:05:00 By Nasdaq GlobeNewswire

G1 Therapeutics to Participate in Two Investor Conferences in March

03 Mar 2021 07:30:00 By Nasdaq GlobeNewswire

G1 Therapeutics and Boehringer Ingelheim Announce Commercial Availability of COSELA™ (trilaciclib), the Only FDA-Approved Multilineage Myeloprotection Therapy to Decrease the Incidence of Chemotherapy-Induced Myelosuppression

02 Mar 2021 06:59:00 By Nasdaq GlobeNewswire

G1 Therapeutics Provides Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights

24 Feb 2021 16:01:00 By Nasdaq GlobeNewswire

G1 Therapeutics to Provide Fourth Quarter and Full Year 2020 Financial Results and Business Update on February 24, 2021

17 Feb 2021 08:00:02 By Nasdaq GlobeNewswire

FDA Approves G1 Therapeutics’ COSELA™ (trilaciclib): The First and Only Myeloprotection Therapy to Decrease the Incidence of Chemotherapy-Induced Myelosuppression

12 Feb 2021 19:40:55 By Nasdaq GlobeNewswire

G1 Therapeutics to Present at the Guggenheim Healthcare Talks: 2021 Oncology Day Virtual Conference

04 Feb 2021 07:30:00 By Nasdaq GlobeNewswire

G1 Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference on January 13, 2021

05 Jan 2021 07:00:00 By Nasdaq GlobeNewswire

G1 Therapeutics Announces Appointment of William C. Roberts as Vice President, Investor Relations & Corporate Communications

04 Jan 2021 07:00:00 By Nasdaq GlobeNewswire